Radiation therapy (RT) for a left-sided breast cancer often involves some incidental exposure of the heart and increase in the rate of major coronary events. One method to reduce the dose to the heart during a tangential breast irradiation is the deep inspiration breath hold (DIBH) technique. Our department adopted DIBH for selected left breast cancer patients with a maximum cardiac distance ≥ 10 mm. We evaluated the effect of the DIBH on cardiac dose compared to normal free breathing (FB). The secondary objective of our present study was to use modeled risk estimates to quantify the risk of coronary events after RT with DIBH. Thirty-two patients who underwent RT with DIBH at our hospital were retrospectively analyzed. For each patient, two computed tomography (CT) scans were acquired, FB-CT and DIBH-CT. Using a deformable image registration tool, the target volume was deformed from DIBH-CT to FB-CT, and conventional tangential treatment planning was performed, focusing on the equality of target coverage between the two plans. Doses to the heart, left anterior descending (LAD) artery, and ipsilateral lung were assessed. By using DIBH, the average mean heart dose was reduced from 724.1 cGy to 279.3 (p < 0.001). The relative heart volume irradiated with 10 Gy–50 Gy was consistently reduced. The mean dose to the LAD coronary artery was reduced from 4079.1 cGy to 2368.9 cGy (p < 0.001). The ipsilateral lung volume receiving 20 Gy or more and 40 Gy or more was reduced by 2.2 % in both cases. Estimated risks of coronary events at 10 years were 4.03 and 2.55 % for RT with FB and DIBH, respectively (p < 0.001). The use of DIBH during RT of the left-sided breast considerably reduces the doses delivered to the heart and LAD artery with similar target coverage. For the current study patients, the probability of major coronary events was reduced with DIBH.

Volumetric-modulated arc therapy (VMAT) is a highly sophisticated linear accelerator-based treatment method, and allows dose rate-changing intensity modulation with gantry rotation. We report our clinical experiences with stereotactic body radiation therapy (SBRT) using a respiratory-gated VMAT technique for patients with hepatocellular carcinoma (HCC) when established curative treatments cannot be applied. A total of 119 patients (139 lesions) with HCC who were treated with SBRT were registered between March 2012 and July 2013 at our institution. A dose of 10–15 Gy per fraction was applied over 3–4 consecutive days, resulting in a total dose of 30–60 Gy. The median follow-up period was 25.8 months (range, 3.2–36.8 months). The overall 3-year survival rate was 83.8%. The local control rate at 3 years was 97.0% in all treated lesions. Multivariate analysis revealed that the Child-Pugh class before SBRT had significant effects on overall survival (Child-Pugh A: hazard ratio = 0.463; 95% CI, 0.262–0.817; p = 0.008). SBRT using a respiratory-gated VMAT technique was an excellent ablative treatment modality for patients with HCC. SBRT is a good alternative treatment for patients with small HCCs that are unsuitable for surgical resection or local ablative therapy.

The aim of this work was to study the feasibility of proton radiography (pRad) as a patient-specific range compensator (RC) quality assurance (QA) tool and to validate its clinical utility by performing QA on RCs having three kinds of possible defects. In order to achieve pRad for a single EBT film, proton beam currents were modulated with new weighting factors, maximizing the linearity of optical-density-to-thickness ratio. Two RCs, examined to be accurately manufactured as planned, were selected to estimate the feasibility of our pRad. The optical densities of the EBT film on which the RC was irradiated with the modulated proton beam were digitized to pixel values (pv) and then converted to thickness using a thickness-pv calibration curve. The thickness information on the pRad was compared with plan data that had been extracted from treatment planning system. The mean thickness difference (TD) over the flat RC regions was calculated as 0.39 mm, and the standard deviation as 0.22 mm, and the proton scattering effect was analyzed by step phantom measurement. Even proton scattering effected a TD of over 1 mm in the large gradient region, the percentage of pixels over the acceptance criterion was only within 1.11% and 3.49%, respectively, when a 1 mm distance to agreement tolerance limit was applied. The QA results for both precisely and imprecisely manufactured RCs demonstrated the high potential utility and clinical applicability of the pRad-based RC QA tool.

In this study, a new three-dimensional (3D) volumetric dosimetry method utilizing gel dosimetry with a patient-specific (PS) 3D-printed phantom was developed. A PS 3D-printed phantom that closely mimics the actual tumor and surrounding tissues was demonstrated using a 3D printer (3Dison Plus, Lokit, Korea). MAGAT normoxic polymer gel was filled in the tumor-shaped cavity of the 3D-printed phantom to represent the real tumor. Seven identical gel samples for dosimetric calibration were irradiated at different doses and scanned using magnetic resonance imaging. A chlorinated polyethylene filament was utilized as the 3D printing material. The two-dimensional gamma passing rates using the film were 96.1% and 84.3% for the 3%/3 mm and the 2%/1 mm dose accuracy/distance-to agreement criteria, respectively. The radiation dose-R2 (relaxation rate) calibration, with a coefficient of determination (R2) of 0.997, was applied for the absolute dose calibration. The overall gross tumor volume shape and the dose distribution of the gel measurement agreed reasonably well with the plan results. The 3D gamma passing rate was 91.2% for the 3%/3 mm criteria and decreased to 82.3% for the 2%/1 mm criterion. Our results suggest that polymer gel dosimetry with the 3D-printed phantom allows direct validation of the 3D dose distribution.